Breast Cancers And Leukemias Slowed By A Single Therapy
The single protein is HSP90, which acts as a chaperone to protect other proteins in the cell.
A team led by Ute Moll at the University of Göttingen in Germany found that blocking HSP90 activity rendered normally protected proteins vulnerable to attack and destruction. One of these proteins - called migration inhibitory factor - drives the growth of breast tumors. HSP90 inhibitors slowed the growth of MIF-expressing breast tumors in mice but had little effect on tumors lacking MIF.
HSP90 inhibitors also look promising for certain forms of leukemia, according to a study by David Weinstock and coworkers at the Dana-Farber Cancer Institute. They showed that HSP90 inhibitors slowed the growth of leukemias driven by hyperactive versions of the enzyme JAK2, many of which become resistant to JAK2-blocking drugs. The HSP90 inhibitors delayed the growth of resistant leukemia cells in mice.
Together these studies suggest that HSP90 may represent a therapeutic target in many cancers.
Schulz, R., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111117
Weigert, O., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111694
Rockefeller University Press
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Rockefeller University Press. "Breast Cancers And Leukemias Slowed By A Single Therapy." Medical News Today. MediLexicon, Intl., 24 Jan. 2012. Web.
22 Jun. 2017. <http://www.medicalnewstoday.com/releases/240669.php>
Rockefeller University Press. (2012, January 24). "Breast Cancers And Leukemias Slowed By A Single Therapy." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.